By Sarah Sorscher*, JD/MPH Candidate, Harvard Law School & Sara Crager, MD/PhD Candidate, Yale Editorial Policy Text of H.R. 1427 Summary Last week, Rep. Henry Waxman and several other representatives unveiled the latest version of a bill designed to lower the price of drugs by encouraging generic competition in biological products (“biologics”). Biologics are products derived from living processes and used to prevent, treat, or cure human illness. Most drugs, in contrast, are synthesized using chemical reactions.  Biologics include products such as vaccines, blood-derived products, antibodies, ... Read More...